News

CVS Health stock has returned 74.8% over the past year, yet its broader valuation checks lean expensive, so investors are weighing a strong share price run against signals that the stock may already be pricing in a lot of good news. Over the last 12 months, CVS Health has delivered a 74.8% return, which puts recent holders in a strong position and naturally raises the bar for what future returns need to justify today’s price. Expectations around CVS Health’s ability to grow healthcare and...

Millions of Medicare Advantage members will open a letter this fall that could quietly close doors they assume will always stay open. What insurers have already decided for 2027 and what enrollees do next could cost thousands of dollars or make coverage impossible to find.

(Bloomberg) -- Executives and investors tied to the AI supply chain were among the biggest insider sellers in the second quarter, taking advantage of a sharp — and volatile — rally in technology stocks.Most Read from BloombergUS Intercepts Iran Attack on Bases, Puncturing Days of CalmSK Hynix Profit Disappoints, Spending Soars to $31 BillionNvidia’s $750 Billion in Deals Reignite Circular AI FearsChip Rout Deepens on Circular Funding, China Competition FearsApple Set to Make Big Smart Home Push

Henry Ford Health has filed a lawsuit against CVS Health (NYSE:CVS) alleging fraudulent reimbursement practices tied to the federal 340B drug discount program. The complaint claims CVS manipulated pricing and engaged in retaliatory behavior, which Henry Ford Health says led to losses of more than US$29 million. The case adds to a series of disputes between large health systems and pharmacy operators over how 340B program discounts are administered. For investors following CVS Health, this...

Insurance carriers need more proof that paying today’s GLP-1 drug prices will create “enough downstream savings,” assuming that people are healthier long term.

Community Health heads into Q2 earnings with mixed operating trends as stronger occupancy meets lower admissions and a smaller hospital portfolio.

The stock's current valuation looks steep, but for a patient holder, the price tag on future earnings tells a very different story.

Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se

(Update with the Justice Department's response to a request for comment in the third paragraph.)

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

Express Scripts, Caremark and Optum Rx sued the FTC after the agency accused them of driving up the cost of insulin. But the countersuit is being put to bed now that the PBMs are settling with regulators.

Florida's Attorney General has opened an investigation into CVS Health's (NYSE:CVS) Caremark pharmacy benefit manager for alleged anticompetitive practices. The probe focuses on claims of steering patients, preferential reimbursement rates, and burdensome audits that may disadvantage independent pharmacies. The investigation centers on Caremark's role in managing prescription drug benefits and its interactions with pharmacies across Florida. CVS Health sits at the intersection of retail...

The investigation by Florida’s attorney general comes as states look to check pharmacy benefit managers for allegedly driving up drug costs.

Florida’s attorney general says he is examining whether CVS’s pharmacy benefit manager steers patients to its own pharmacies.

CVS Health is rolling out a first of its kind aluminum bottle for store branded over the counter products across its national pharmacy network. The company is also funding mobile maternal health clinics in underserved rural areas of Missouri, focused on prenatal and mental health services. These moves expand CVS Health’s sustainability and community health efforts beyond its core retail and insurance operations. For investors watching NYSE:CVS, these announcements add context around how the...

CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions of dollars in savings tied to the federal 340B drug discount program. At the same time, CVS Health is expanding access to GLP-1 weight management drugs through new formulary decisions, including the reintroduction of Zepbound and removal of barriers for Foundayo. These developments come as pharmacy benefit manager practices receive increased attention from regulators...

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of Michigan Hospitals and Health Centers allege CVS Health improperly profited from 340B discounts. Combined claimed damages exceed $60 million, raising legal, financial, and reputational questions for the company. CVS Health comes into this legal pressure with its shares at $93.28 and a return of...

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Healthcare stocks have had a rough stretch. Rising medical costs, Medicaid pressure, and persistent skepticism about managed care margins have kept investors on edge all year. Walking into a CVS Health earnings report in that environment felt like bracing for bad news. The bad news, however, didn't ...